Background: Meta-analyses suggest that Vit. A supplementation may reduce CLD and sepsis in ELBW infants. Our pilot studies supported use of a higher dose (5,000 IU given IM 3 times/wk for 4 wks) than that used in most neonatal trials. Purpose: To assess the effectiveness and safety of this regimen for infants 401-1000g BW who required oxygen or mechanical ventilation at 24h age. Methods: Control infants received a sham procedure to mask clinical staff and examiners. All infants had weekly physical exams for signs of toxicity; a sample (n=301) had serum analyses in a central lab with documented reliability. A sample size of 800 infants was planned to identify a ≥20% reduction (alpha error 0.05; power 80%) in CLD(oxygen dependence at 36 wks postmenstrual age) or death by 36 wks. Results: 405 Vit. A infants and 402 Controls with a similar mean BW(770, 769g) and GA (26.8, 26.7wks) were enrolled at 24-96 h age.Effectiveness: Death before discharge occurred in 17% of both groups. CLD or death by 36 wks--the primary outcome variable--occurred less often in Vit. A infants than Controls (55% vs. 62%; p=0.029; Relative Risk[RR] =0.89, 95%CI=0.80-0.99). Similar albeit not significant risk reductions were noted for sepsis (RR = 0.90; 95%CI=0.76-1.07), periventricular leukomalacia (PVL) (RR=0.74; 95%CI=0.44-1.25), and the combined outcome of death, Grade 3/4 intracranial hemorrhage, or PVL (RR=0.92; 95% CI=0.76-1.12).Safety: Questionable or definite increased fontanelle tension--considered the most sensitive sign of Vit. A toxicity--was found in 15% of Vit. A infants and 18% of Controls on any exam (p=0.25). Vit. A toxicity was suspected from physical findings in 1.0% of Vit. A infants and 0.8% of Controls (p=0.72). At study day 28, low serum retinol values(<20μg/dl, a value <5 percentile in U.S. children) were observed in a sizable proportion of Vit. A infants (24%) albeit a lower percentage than in Controls (55%) (p<0.001). A high retinol dose response suggesting low or absent stores of vit. A (>10% increase 3h after 2000 IU/kg IM) was observed in 22% of Vit. A infants and 45% of Controls Conclusion: Given the significant though modest reduction in CLD, the high safety and low cost of the intervention, and the lack of evidence supporting conventional vitamin A regimens, our findings support routine clinical use of the vitamin A regimen tested for infants <1000g BW requiring respiratory support at 24h age. Because even supplemented infants may be vitamin A deficient, higher doses deserve future study.
Additional information
for the NICHD Neonatal Research Network
Rights and permissions
About this article
Cite this article
Tyson, J., Ehrenkranz, R., Stoll, B. et al. Vitamin (Vit.) A Supplementation to Increase Survival without Chronic Lung Disease (CLD) in Extremely Low Birth Weight (ELBW) Infants: A 14-Center Randomized Trial • 1161. Pediatr Res 43 (Suppl 4), 199 (1998). https://doi.org/10.1203/00006450-199804001-01182
Issue Date:
DOI: https://doi.org/10.1203/00006450-199804001-01182